Empagliflozin was associated with significant improvements in cardiovascular risk factors, A1C rates and body weight at 24 weeks in type 2 diabetes patients, data presented at the American Diabetes Association's 73rd Scientific Sessions indicated. Researchers also found that among patients with uncontrolled blood pressure at baseline, 33.3% of those who took empagliflozin at 10 mg/day and 32.2% of those who took 25 mg/day had regulated blood pressure at week 24, compared with 18.6% in the placebo group.

Related Summaries